© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Managing Vasomotor Symptoms of Menopause: A Topline Comparison of Treatments
May 13, 2025
Medical and nonpharmacologic treatment options for VMS range in efficacy and risk/benefit profile; a short slide show offers a topline look at how many compare.
A Half Dose of Semaglutide Yields Weight Loss Equivalent to Clinical Trial Doses in Combination with Online Support Program
May 13, 2025
Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.
FDA Clears STS101 Nasal Powder for Acute Treatment of Migraine: Daily Dose
May 13, 2025
Your daily dose of the clinical news you may have missed.
FDA Approves First At-Home Pap Smear Alternative for Cervical Cancer Screening, from Teal Health
May 12, 2025
The Teal Wand allows women to collect a vaginal sample in the privacy of their home and, according to Teal Health, the test has 96% accuracy for cervical precancer.
Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study
May 12, 2025
Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.
Novel TK1 Inhibitor Demonstrates Rapid, Dose-Dependent Efficacy in Atopic Dermatitis in Ph 1 Trial
May 12, 2025
Adults receiving the highest dose achieved 2 times the reduction in EASI scores vs placebo with responses emerging as early as day 8 of treatment.
Genetic Risk Score Identifies Individuals Likely to Report Adverse Events from GLP-1 Mimetic Therapy
May 12, 2025
The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.
Tirzepatide Associated with Improved HF Symptoms, Renal Function in People with Obesity, CKD: Daily Dose
May 12, 2025
Your daily dose of the clinical news you may have missed.
LEO Pharma Announces Positive Preliminary Phase 2b Findings for Temtokibart in Atopic Dermatitis
May 09, 2025
The IL-22FA1 antagonist achieved positive outcomes for the primary endpoint based on percentage change in EASI from baseline to week 16 for 3 highest doses, according to LEO.
Crinecerfont Reduces GC Dosing, Improves Androstenedione Levels Across Multiple Pediatric Subgroups
May 09, 2025
Data for GC reduction and improved A4 levels were consistent across subgroups stratified by sex, race, age, BMI, and baseline A4 levels, according to Neurocrine Biosciences.